Table 3.

Associations of rs1893217 and rs17388568 with response in anti-CTLA-4 and anti-PD-1 under different genetic models^a

	Additive model		Dominant model		Recessive model
	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value
Anti-CTLA-4b rs1893217
AA	Reference	Reference	Reference	Reference	Reference	Reference
AG	2.26 (1.21–4.20)	0.01	2.79 (1.36–5.73)	0.005	1.89 (0.35–10.11)	0.45
GG	5.11 (2.97–9.51)	0.01
Anti-PD-1c rs17388568
GG	Reference	Reference	Reference	Reference	Reference	Reference
GA	0.38 (0.21–0.67)	0.0008*	0.26 (0.12–0.53)	0.0002*	0.38 (0.11–1.33)	0.13
AA	0.14 (0.08–0.25)	0.0008*

Asterisk (*) indicates p value surpassing the Bonferroni multiple testing adjustment (p < 0.002)

^aModels adjusted for age, sex and treatment drug (ipilimumab or tremelimumab; nivolumab or pembrolizumab)

^bN controls = 78, N cases = 135 (controls: ICI responders; cases: ICI non-responders); for the dominant model: the genotype group comparisons were as follows: AA (reference) vs AG/GG; for the recessive model: AA/AG (reference) vs GG

^cN controls = 88, N cases = 81 (Controls: ICI responders; Cases: ICI non-responders) ; for the dominant model: the genotype group comparisons were as follows: GG (reference) vs GA/AA; for the recessive model: GG/GA (reference) vs AA